Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM

Learn more about:
Related Clinical Trial
Feasibility of [11C]Acetate-Positron Emission Tomography (PET) in Lymphangioleiomyomatosis and Tuberous Sclerosis Complex Lymphangioleiomyomatosis, a Study on Cathepsin K Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy KidneYou – Innovative Digital Therapy Gait in Rare Diseases Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Doxycycline In Lymphangioleiomyomatosis (LAM) Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women Turmeric as Treatment in Epilepsy Study of the Disease Process of Lymphangioleiomyomatosis RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM The Effectiveness and Safety of Vagus Nerve Stimulation for TRE The Effectiveness and Safety of Resective Epilepsy Surgery for TRE Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) Safety of Simvastatin in LAM and TSC Studies of Autistic Patients: Gene Networks and Clinical Subtypes Topical Rapamycin to Erase Angiofibromas in TSC Rapalogues for Autism Phenotype in TSC: A Feasibility Study A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Everolimus for Cancer With TSC1 or TSC2 Mutation Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex The Cognitive Variability in NF1 and TSC Monozygotic Twins Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy – Tuberous Sclerosis Complex A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex JASPER Early Intervention for Tuberous Sclerosis Studies in Patients With Tuberous Sclerosis Complex Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex (TuScCom) Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) Tuberous Sclerosis Complex Natural History Study: Renal Manifestations Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) Study of Skin Tumors in Tuberous Sclerosis

Brief Title

Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM

Official Title

A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis

Brief Summary

      The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor
      sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis
      complex or sporadic lymphangioleiomyomatosis.

Detailed Description

      Inherited mutations of the TSC1 or TSC2 gene cause tuberous sclerosis while acquired
      (somatic) mutations of either gene are associated with sporadic lymphangioleiomyomatosis
      (LAM). Renal angiomyolipomas are a feature of both disorders. TSC1 and TSC2 regulate
      signalling through the mammalian target of rapamycin (mTOR) pathway. Inhibition of mTOR may
      result in a decrease in size of TSC 1/2 assciated lesions. We are treating patients with
      tuberous sclerosis or sporadic LAM with the mTOR inhibitor rapamycin in a non-randomised,
      open label pilot study of safety and efficacy. Change in size of renal angiomyolipomas is the
      primary end point

Study Phase

Phase 2

Study Type


Primary Outcome

longest diameter of renal angiomyolipomas assessed by MRI scan, toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0

Secondary Outcome

 respiratory function tests (FEV1, FVC, DLCO), cognitive function (memory, executive skills)


Tuberous Sclerosis




* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 2005

Completion Date

September 2009

Primary Completion Date

September 2009

Eligibility Criteria

        Inclusion Criteria:

          -  If female, documentation of negative pregnancy test prior to enrolment.

          -  Participants, including males, must use an effective form of contraception, whilst
             taking sirolimus and for twelve weeks after stopping the drug

          -  One or more renal angiomyolipomata of at least two centimetres or greater in largest

          -  Adequate renal function :glomerular filtration rate > 40 ml/min

          -  Clinically definite diagnosis of tuberous sclerosis (modified Gomez criteria) or
             sporadic LAM (biopsy-proven or compatible high resolution chest CT scan and
             respiratory function tests.)

          -  Signed and dated informed consent

        Exclusion Criteria:

          -  History of non-compliance or inability to give informed consent

          -  Significant haematological or hepatic abnormality (i.e. transaminase levels > 150
             i.u./L serum albumin < 30 g/L, haematocrit< 30%, platelets < 100,000/ mm3, adjusted
             absolute neutrophil count < 1,500/mm3, total WBC < 3,000/ mm3)

          -  Greater than 1 g proteinuria daily

          -  Multiple bilateral AMLs, where individual lesions cannot be distinguished

          -  Renal haemorrhage within preceding year

          -  In those who have had a renal haemorrhage, known conservatively managed renal
             aneurysm(s) greater than 10mm

          -  Patients who have had embolisation for AML(s) within the preceding 6 months

          -  Patients who are unable to walk 100 metres on the flat

          -  Continuous requirement for supplemental oxygen

          -  Patients who have had or are being considered for organ transplant

          -  Uncontrolled hyperlipidaemia

          -  Intercurrent infection at initiation of Sirolimus

          -  Surgery within last 2 months

          -  Pregnant or lactating women

          -  Use of an investigational drug within the last 30 days

          -  Change in anti epileptic drug medication within the last 3 months

          -  Likely to need vaccination e.g. for travel during the course of the trial (except for
             influenza vaccine in patients with LAM)

          -  Current usage of strong inhibitors of CYP3AE ( such as ketoconazole, voriconazole,
             itraconazole, tilithromycin or clarithromycin) or strong inducers (such as rifampicin
             or rifabutin)




18 Years - 65 Years

Accepts Healthy Volunteers



Julian R Sampson, DM, , 

Location Countries

United Kingdom

Location Countries

United Kingdom

Administrative Informations



Organization ID


Study Sponsor

Cardiff University


 University of Nottingham

Study Sponsor

Julian R Sampson, DM, Principal Investigator, Cardiff Univeristy

Verification Date

April 2008